Urinary markers for bladder cancer

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Smith, Zachary L ^a   Guzzo, Thomas J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; COMPLEMENT FACTOR H; CYTOKERATIN 18; CYTOKERATIN 8; INHIBITOR OF APOPTOSIS PROTEIN; MARKER; NUCLEAR MATRIX PROTEIN 22; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN 185 KDA; UNCLASSIFIED DRUG; URINARY MARKER;

ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CHROMOSOME 17; CHROMOSOME 21; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9P; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; INCIDENCE; MICROSCOPY; MITOSIS; TUMOR CELL LINE; UNITED STATES;

EID: 84880078681     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-21     Document Type: Article

References (62)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Ro JY, Staerkel GA, Ayala AG: Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992, 19:435-53.
3. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC: A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002, 89:369-73. (Pubitemid 34304360)
4. Soloway MS, Sofer M, Vaidya A: Contemporary management of stage Tl transitional cell carcinoma of the bladder. J Urol 2002, 167:1573-83. (Pubitemid 34240678)
5. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R: The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-30. (Pubitemid 38041357)
6. Lokeshwar VB, Soloway MS: Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001, 165:1067-77. (Pubitemid 32210202)
7. Svatek RS, Sagalowsky AI, Lotan Y: Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 2006, 24:338-43. (Pubitemid 43963410)
8. Van Der Poel HG, Debruyne FM: Can biological markers replace cystoscopy? An update. Curr Opin Urol 2001, 11:503-9. (Pubitemid 32783698)
9. Herr HW: The natural history of a Tl bladder cancer: life-long tumour diathesis. BJU Int 1999, 84:1102-3.
10. Botteman MF, Pashos CL, Hauser RS, Laskin BL, Redaelli A: Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res 2003, 12:675-88. (Pubitemid 37094030)
11. Herr HW, Schneider M: Outpatient flexible cystoscopy in men: a randomized study of patient tolerance. J Urol 2001, 165:1971-2.
12. Babjuk M, Soukup V, Pesl M, Kostfrova M, Drncova E, Smolova H, Szakacsova M, Getzenberg R, Pavlfk I, Dvoracek J: Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapTI bladder urothelial carcinoma. Urology 2008, 71:718-22. (Pubitemid 351447297)
13. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Drager BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ: Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005, 66:35-63. (Pubitemid 43049608)
14. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths T R L, N'Dow J, Nabi G, CookJ, Vale L: Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010, 14:1-331 iii-iv.
15. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM: The accuracy of urinary cytology in daily practice. Cancer 1999, 87:118-28. (Pubitemid 29289245)
16. Planz B, Jochims E, Deix T, Caspers HP, Jakse G, Boecking A: The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol 2005, 31:304-8. (Pubitemid 40361523)
17. Lotan Y, Roehrborn CG: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003, 61:109-18 discussion 118. (Pubitemid 36151724)
18. Larre S, Catto J W F, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB: Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol 2013, 63:1049-58.
19. Bangma CH, Loeb S, Busstra M, Zhu X, Bouazzaoui SE, Refos J, Van Der Keur KA, Tjin S, Franken C G AM, Van Leenders G J LH, Zwarthoff EC, Roobol MJ: Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers. Eur Urol 2013.
20. Hajdinjak T: UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008, 26:646-51.
21. Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, Mattarelli G, Eichenberger T, Dalquen P, Spieler P, Schoenegg R, Gasser TC, Sulser T, Forster T, Zellweger T, Casella R, Bubendorf L: The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 2009, 124:2899-904.
22. Mengual L, Marin-Aguilera M, Ribal MJ, Burset M, Villavicencio H, Oliver A, Alcaraz A: Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol 2007, 52:752-9. (Pubitemid 47126159)
23. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, Blute MM, Lieber MM, Zincke H, Halling KC: Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005, 173:401-4.
24. Schlake A, Crispen PL, Cap AP, Atkinson T, Davenport D, Preston DM: NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study. Can J Urol 2012, 19:6345-50.
25. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A: Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999, 162:53-7. (Pubitemid 29420879)
26. Mian C, Maier K, Comploj E, Lodde M, Berner L, Lusuardi L, Palermo S, Vittadello F, Pycha A: uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006, 108:60-5. (Pubitemid 43291246)
27. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, Van Rhijn BW, Karakiewicz PI: ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 2013, 63:4-15.
28. Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E, Lodde M, Horninger W, Pycha A: uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: An update on 7422 analyses. Cancer Cytopathol 2013.
29. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I: Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999, 161:443-6.
30. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y: Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005, 293:810-6. (Pubitemid 40250364)
31. Miyanaga N, Akaza H, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K: Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol 1999, 6:173-7. (Pubitemid 30406838)
32. Van Le T, Myers J, Konety BR, Barder T, Getzenberg RH: Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res 2004, 10:1384-91. (Pubitemid 38365233)
33. Van Le T, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH: Highly specific urine-based marker of bladder cancer. Urology 2005, 66:1256-60. (Pubitemid 41797301)
34. Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M, Pycha A: Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000, 56:228-31. (Pubitemid 30495572)
35. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M: Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998, 159:1876-80. (Pubitemid 29190716)
36. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, De Vere White R, Sheinfeld J, Jarowenko MV, Schellhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA, Brunelle SL: Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 1997, 50:349-53. (Pubitemid 27428110)
37. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, Pansadoro V, Sternberg CN, Boccon-Gibod L, Ravery V, Le Guludec D, Meulemans A, Conort P, Ishak L: Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999, 45:472-7. (Pubitemid 29165956)
38. Heicappell R, Wettig IC, Schostak M, Müller M, Steiner U, Sauter T, Miller K: Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999, 35:81-7. (Pubitemid 29080555)
39. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL: Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997, 50:882-7.
40. Sánchez-Carbayo M, Urrutia M, Silva JM, Romaní R, De Buitrago JM, Navajo JA: Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001, 165:1462-7.
41. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D: Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002, 94:2914-22. (Pubitemid 34547690)
42. Pariente JL, Bordenave L, Jacob F, Gobinet A, Leger F, Ferriere JM, Le Guillou M: Analytical and prospective evaluation of urinary cytokeratin 19fragmentinbladdercancer. JUrol2000, 163:11 16-9. (Pubitemid 30169374)
43. Sawczuk IS, Pickens CL, Vasa UR, Ralph DA, Norris KA, Miller MC, Ng AY, Grossman HB, Veltri RW: DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol Oncol 2002, 7:185-90.
44. Gilbert SM, Veltri RW, Sawczuk A, Shabsigh A, Knowles DR, Bright S, O'Dowd GJ, Olsson CA, Benson MC, Sawczuk IS: Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Urology 2003, 61:539-43. (Pubitemid 36294186)
45. Hughes JH, Katz RL, Rodriguez-Villanueva J, Kidd L, Dinney C, Grossman HB, Fritsche HA: Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 1999, 20:285-90. (Pubitemid 29205522)
46. Takashi M, Schenck U, Kissel K, Leyh H, Treiber U: Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients. Int Urol Nephrol 1999, 31:189-96. (Pubitemid 29410371)
47. Gutiérrez Baños JL, Martín García B, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, Del Valle Schaan JI, Roca Edreira A, Villanueva Peña A, Gutíerrez García R, De Diego Rodríguez E, Rado Velázquez MA: Utilidad del BTA Stat TEST (Bard) en el diagnóstico del cáncer vesical. Resultados preliminares y comparación con citología y cistoscopia. Arch Esp Urol 1998, 51:778-82. (Pubitemid 128520665)
48. Del Nero A, Esposito N, Curro A, Biasoni D, Montanari E, Mangiarotti B, Trinchieri A, Zanetti G, Serrago MP, Pisani E: Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur Urol 1999, 35:93-7. (Pubitemid 29080239)
49. Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I: Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 1998, 52:793-6. (Pubitemid 28489703)
50. Witjes JA, Van Der Poel HG, Van Balken MR, Debruyne FM, Schalken JA: Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 1998, 33:387-91. (Pubitemid 28230263)
51. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006, 295:299-305. (Pubitemid 43112958)
52. Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhäusser H, Bierfreund H, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Brüning T, Stenzl A: Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the Uro Screen study. BJU Int 2012, 110:699-708.
53. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-9. (Pubitemid 38019195)
54. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC: Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001, 285:324-8. (Pubitemid 32095036)
55. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004, 171:626-30. (Pubitemid 38090444)
56. Sumi S, Arai K, Kitahara S, Yoshida KI: Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 2000, 296:111-20. (Pubitemid 30243144)
57. Olsson H, Zackrisson B: Immuno Cyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 2001, 35:280-2. (Pubitemid 32906848)
58. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M: Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999, 161:1486-9. (Pubitemid 29420801)
59. Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA: Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 2001, 58:367-71. (Pubitemid 32816352)
60. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, Bouchot O, Beurton D, Coulange C, Rambeaud J: Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003, 169:921-4. (Pubitemid 36188123)
61. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M, Flom K: Clinical evaluation of a multitarget fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002, 168:1950-4.
62. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O'Kane DJ, Seelig SA, Lieber MM, Jenkins RB: A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000, 164:1768-75.